Surabhi Dangi-Garimella, PhD

The path to President Obama's Precision Medicine Initiative has been paved as is evident from a report released by a Working Group convened by the National Institutes of Health.

Scientists in Spain have identified gene mutations that trigger bone metastasis in breast cancer patients.

At the recently held NCCN healthcare policy summit in Washington, DC, experts delved into various models being evaluated to reduce healthcare utilization in oncology care.

Healthcare policy makers, payers, medical centers, and patient representatives shared the dais as they discussed The Value Proposition in oncology.

Metastatic melanoma patients treated with pembrolizumab responded better if their T cells had a higher level of Bim expression.

The American Journal of Managed Care spoke with Bruce J. Gould, MD, medical director of Northwest Georgia Oncology Centers on the impact of the 340B drug pricing program on private oncology practices.

The study, published in the journal Cancer, found that non-biological factors are as important as biological variables in shaping outcomes in young patients with leukemia.

Healthcare policy experts gathered in Washington, DC, to discuss access, cost, and the definition of value in oncology care.

CVS Health says narrow networks improve medication adherence in patients with chronic diseases.

An abstract presented at the 16th World Conference on Lung Cancer presented results from a study that monitored irAEs resulting from treatment with immune checkpoint inhibitors.

Presented at the ongoing World Conference on Lung Cancer, the trial has identified 7 actionable genomic alterations in lung cancer patients under 40 years of age.

At the end of CMS' comment period, the American Society of Clinical Oncology submitted its comments and recommendations for the proposed changes.

The California Public Employees' Retirement System saved $7 million on screening colonoscopies during a 2-year period following implementation of reference pricing.

The drug, approved in Japan last year, had been granted Breakthrough Therapy designation by the FDA.

With a new dosing schedule, low toxicity and a PD-L1 expression-driven response was observed.

With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.

Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.

Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.

Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.

Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.

A study evaluating EHRs has identified ways to make them more efficient for physicians, with the goal of improving patient care.

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

When measuring quality of pediatric care, hospitals should include different-hospital readmission along with same-hospital readmission, the authors conclude.

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.